The U. S. Patent Office granted Rosetta Genomics Ltd. (Nasdaq: ROSG) a patent
for cancer therapeutics. Rosetta Genomics also received its first
European patent allowance for its Cancer of Unknown Primary testing
franchise miR-451. The stock price leaped $1.48 to $5.13.
Rosetta Genomics receives patents
February 17, 2015 at 11:48 AM EST
